MLN0128 (INK128), an Investigational Oral Dual TORC1/2 Inhibitor, in Patients (pts) with Relapsed or Refractory Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), or Waldenstrom Macroglobulinemia (WM): Preliminary Results From a Phase 1 Dose-Escalation Study

被引：1

作者：

Ghobrial, Irene M. ^{[1
,2
]}

Siegel, David ^{[3
]}

Vij, Ravi ^{[4
]}

Wolf, Jeffrey L. ^{[5
]}

Berdeja, Jesus G. ^{[6
]}

Matous, Jeffrey V. ^{[7
]}

Lipman, Peter ^{[8
]}

Patel, Chirag ^{[8
]}

Le, Trinh ^{[9
]}

Rommel, Christian ^{[9
]}

Berk, Gregory ^{[8
]}

机构：

[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA

[2] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Ctr Multiple Myeloma Res, Boston, MA 02115 USA

[3] Hackensack Univ Med Ctr, Hackensack, NJ USA

[4] Washington Univ Sch Med, Div Oncol, Dept Med, St Louis, MO USA

[5] Univ Calif San Francisco, San Francisco, CA 94143 USA

[6] Sarah Cannon Res Inst, Nashville, TN USA

[7] Colorado Blood Canc Inst, Denver, CO USA

[8] Millennium Pharmaceut Inc, Cambridge, MA USA

[9] Intellikine LLC, La Jolla, CA USA

来源：

BLOOD | 2012年 / 120卷 / 21期

关键词：

D O I：

10.1182/blood.V120.21.4038.4038

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4038

引用

页数：2

共 50 条

[41] LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenstrom's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from the Phase 1/2 BRUIN Study
Wang, Michael
Shah, Nirav N.
Alencar, Alvaro J.
Gerson, James N.
Patel, Manish R.
Fakhri, Bita
Jurczak, Wojciech
Tan, Xuan Ni
Lewis, Katharine L.
Fenske, Timothy S.
Coombs, Catherine C.
Flinn, Ian W.
Lewis, David John
Le Gouill, Steven
Palomba, M. Lia
Woyach, Jennifer A.
Pagel, John M.
Lamanna, Nicole
Cohen, Jonathon B.
Barve, Minal
Ghia, Paolo
Eyre, Toby A.
Yin, Ming
Nair, Binoj
Tsai, Donald
Ku, Nora C.
Mato, Anthony
Cheah, Chan Yoon
BLOOD, 2020, 136
[42] MBS303, a Novel 2:1 CD20xCD3 Bispecific Antibody, Demonstrated a Favorable Safety and Potent Antitumor Activity in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma: Preliminary Results from a Phase I , Dose-Escalation Trial
Song, Yuqin
Yang, Haiyan
Jia, Youchao
Sheng, Lixia
Deng, Lijuan
Chen, Xi
Tang, Yongjing
Liu, Xifang
Liu, Sijun
Wei, Min
Li, Feng
BLOOD, 2024, 144 : 6481 - 6482
[43] Umbralisib, the Once-Daily Dual Inhibitor of PI3Kδ and Casein Kinase-1e Demonstrates Clinical Activity in Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results From the Phase 2 Global UNITY-NHL Trial
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 4 - 5
[44] LOXO-305, A Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenstrom's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results From the Phase 1/2 BRUIN Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (04) : 13 - 14
[45] Clinical Activity of CC-99282, a Novel, Oral Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients (Pts) with Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) - First Results from a Phase 1, Open-Label Study
Michot, Jean-Marie
Chavez, Julio C.
Carpio, Cecilia
Ferrari, Silvia
Feldman, Tatyana A.
Morillo, Daniel
Kuruvilla, John
Pinto, Antonio
Ribrag, Vincent
Bachy, Emmanuel
Buchholz, Tonia J.
Carrancio, Soraya
Guarinos, Carla
Wu, Fan
Li, Shaoyi
Patah, Poliana
Pourdehnad, Michael
Nastoupil, Loretta
BLOOD, 2021, 138
[46] Preliminary results from the Phase I part of a first-in-human Phase I/II study of HH2853, an EZH1/2 inhibitor, in patients with relapsed/refractory non-Hodgkin lymphomas or advanced solid tumors
Fan, Zhengfu
Wang, Jin
Fang, Meiyu
Patrick, Johnston
Han, Tun
Sommerhalder, David
Gong, Jifang
Yang, Jilong
Yang, Yun
Munoz, Javier
Song, Yuqin
Li, Zhiming
Li, Xian'an
Ma, Qiuying
Han, Jinming
Shen, Lin
Zhu, Jun
CANCER RESEARCH, 2023, 83 (08)
[47] A phase I, open-label study of GSK2816126, an enhancer of zeste homolog 2 (EZH2) inhibitor, in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (tFL), other non-Hodgkin's lymphomas (NHL), multiple myeloma (MM) and solid tumor.
Yap, Timothy Anthony
Johnson, Peter W. M.
Winter, Jane
Leonard, John
Giulino-Roth, Lisa
Horner, Thierry
Radswillas, Kristen
Carver, Jennifer
Dhar, Arindam
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[48] Glofitamab Plus R-CHOP Induces High Response Rates with Minimal Cytokine Release Syndrome (CRS) in Patients (pts) with Relapsed/Refractory (R/R) NonHodgkin Lymphoma (NHL) and Previously Untreated (1L) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results from a Dose-Escalation and Safety Run-in Phase Ib Study
Ghosh, Nilanjan
Townsend, William
Dickinson, Michael
Topp, Max
Tani, Monica
Santoro, Armando
Crump, Michael
Morschhauser, Franck
Le Gouill, Steven
Mehta, Amitkumar
Panchal, Anesh
Wu, Chun
Barrett, Martin
Humphrey, Kathryn
Qayum, Naseer
Hutchings, Martin
BLOOD, 2021, 138
[49] Preliminary Safety and Efficacy Evaluation of IMM0306, a CD47 and CD20 Bispecific Monoclonal Antibody-Trap (mAbTrap), from an Ongoing Phase I Dose-Escalation Study in Patients with Relapsed or Refractory B-Cell Non- Hodgkin's Lymphoma (R/R B-NHL)
Shi, Yuankai
Song, Yongping
Zhang, Mingzhi
Jing, Hongmei
Wang, Zhen
Li, Zhiming
Qi, Junyuan
Li, Fei
Li, Wenyu
Yang, Jianliang
Gao, Siman
Ma, Huizi
He, Heming
Lu, Qiying
Tian, Wenzhi
BLOOD, 2022, 140 : 9323 - 9324
[50] CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002
Richardson, Paul G.
Ocio, Enrique
Raje, Noopur S.
Gregory, Tara
White, Darrell
Oriol, Albert
Sandhu, Irwindeep
Raab, Marc-Steffen
Le Blanc, Richard
Rodriguez, Cesar
Trudel, Suzanne
Waesch, Ralph
Perrot, Aurore
Bahlis, Nizar J.
Zhou, Zehua
Lamba, Manisha
Amatangelo, Michael
Civardi, Tiziana
Katz, Jessica
Aciag, Paulo M.
Peluso, Teresa
Dimopoulos, Meletios A.
BLOOD, 2021, 138

← 1 2 3 4 5 →